Skip to main content
SpringerLink
Log in

Asfotase-α benefits too uncertain to justify high cost, says NICE

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • NICE. Benefits of new drug to treat rare inherited bone disorder too uncertain to justify its high cost says NICE in draft guidance. Media Release : 3 Dec 2015. Available from: URL: http://www.nice.org.uk

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Asfotase-α benefits too uncertain to justify high cost, says NICE. PharmacoEcon Outcomes News 743, 33 (2015). https://doi.org/10.1007/s40274-015-2698-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-2698-1

Search

Navigation